Press Coverage

Dr. Gregory Kennedy: A Novel Technology for the Early Detection of Lung Cancer

18 July 2022

Recently, a category-leading proof-of-concept study, “Targeted Detection of Cancer at the Cellular Level During Biopsy by Near-Infrared Confocal Laser Endomicroscopy,” was published in Nature Communications.

The study demonstrated the use of On Target’s intraoperative molecular imaging agent, CYTALUX™ (pafolacianine) injection, in conjunction with Mauna Kea’s U.S. FDA 510(k) cleared Cellvizio® platform for the detection of cancer cells during biopsy procedures. The new approach has the potential to help physicians diagnose lung cancer in earlier stages.

DocWire News spoke with Gregory Kennedy, MD, a resident in General Surgery at the University of Pennsylvania, and one of the study’s principal investigators, about the analysis and its implications.

Latest News

Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates

Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates

PANCREATIC CANCER AWARENESS MONTH: UNDERSTANDING CELLVIZIO® IN CLINICAL PRACTICE 

PANCREATIC CANCER AWARENESS MONTH: UNDERSTANDING CELLVIZIO® IN CLINICAL PRACTICE 

Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 

Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 

No results found.